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Abstract 
Hypoglycemia is associated with increased cardiovascular mortality in trials of intensive 
therapy in type 2 diabetes (T2DM). We previously observed an increase in arrhythmias 
during spontaneous prolonged hypoglycemia in T2DM patients. Our aim was to examine 
changes in cardiac autonomic function and repolarization during sustained experimental 
hypoglycemia. 
Twelve adults with T2DM and eleven age, BMI-matched nondiabetic controls underwent 
paired hyperinsulinemic clamps separated by 4 weeks. Glucose was maintained at 
euglycemia (6.0mmol/L) or hypoglycemia (2.5mmol/L) for one hour. Heart rate, blood 
pressure, heart rate variability were assessed every thirty minutes and corrected QT (QTc) 
and T wave morphology every 60 minutes. 
Heart rate initially increased in T2DM participants but then fell towards baseline despite 
maintained hypoglycemia at 1 hour, accompanied by reactivation of vagal tone.  In 
nondiabetic participants, vagal tone remained depressed during sustained hypoglycemia. 
Diabetic participants exhibited greater heterogeneity of repolarization during hypoglycemia 
as demonstrated by T wave symmetry and Principal Component Analysis (PCA) ratio 
compared with the nondiabetic group. Epinephrine levels during hypoglycemia were similar 
between groups.   
Cardiac autonomic regulation during hypoglycemia appears time-dependent. T2DM 
individuals demonstrate greater repolarization abnormalities for a given hypoglycemic 
stimulus despite comparable sympathoadrenal responses. These mechanisms could contribute 
to arrhythmias during clinical hypoglycemic episodes. 
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Glossary 
BRS - baroreceptor sensitivity 
BMI – body mass index 
CVD - cardiovascular disease 
ECG - electrocardiogram 
HRV - heart rate variability 
HF - high frequency (power of heart rate variability) 
LF - low frequency (power of heart rate variability) 
LFnorm - normalized low frequency (power of heart rate variability) 
NN - normal-to-normal RR intervals 
PCA ratio – principal component analysis ratio 
RMSSD - root mean square of successive differences in NN 
SDNN - standard deviation of NN  
T2DM- type 2 diabetes mellitus 
TCRT – total cosine R to T 
TWLD – T wave loop dispersion  
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Recent large trials of intensive glycemic control involving individuals with type 2 
diabetes (T2DM) have not reduced cardiovascular death in type 2 diabetes patients at high 
cardiovascular risk (1; 2) and in one trial was associated with increased mortality (3). Severe 
hypoglycemia was increased several fold in the intensive control arm in all three trials and 
was a strong independent predictor of mortality in post hoc analyses (4). Hypoglycemia is a 
plausible explanation for the observed excess mortality but evidence for a direct mechanistic 
link remains unclear. Recent studies of insulin therapy in T2DM have shown a higher risk of 
fatal arrhythmic death associated with severe hypoglycemia (5). One mechanism by which 
hypoglycemia could promote arrhythmias is through changes in cardiac autonomic activity 
and repolarization. 
In a recent study examining ECG responses to spontaneous hypoglycemia in type 2 diabetes 
patients using ambulatory glucose and Holter monitoring (6), we observed an increase in 
bradycardia and atrial ectopic activity during hypoglycemia when compared to euglycemia. 
During nocturnal hypoglycemic episodes when glucose was generally lower and episodes 
more prolonged, we observed a phased response whereby initial increases in heart rate were 
followed by a relative bradycardia.  We speculated that this may reflect diurnal differences in 
the depth and duration of hypoglycemia, leading to differential sympathetic and 
parasympathetic stimulation varying over time. However, in spontaneous clinical episodes 
neither the depth or duration can be controlled and it is not possible to measure circulating 
catecholamines or electrolytes which are relevant to these responses. 
In the same study, we observed a higher rate of ventricular ectopic activity during 
hypoglycemia compared with euglycemia; other studies have also reported higher rates of 
ventricular tachyarrhythmias during spontaneous hypoglycemic episodes (7). This could be 
related to abnormal cardiac repolarization which we have previously demonstrated during 
experimental and spontaneous hypoglycemia (8).  Individuals with type 2 diabetes (with 
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varying degrees of autonomic dysfunction) exhibit longer baseline QT intervals than non-
diabetic individuals which is associated with increased mortality (9).  In our recent 
ambulatory study, we observed QT prolongation in excess of 500ms with gross 
morphological changes in T waves in some individuals (6).  
Our primary aim was to examine changes in cardiac autonomic regulation and repolarization 
during controlled sustained experimental hypoglycemia as potential mechanisms that may 
provoke cardiac arrhythmias. We hypothesized that there are phasic changes in cardiac 
autonomic response that may occur during sustained hypoglycemia. Responses in T2DM 
individuals were compared against nondiabetic individuals as a control group. 
Research Design and Methods 
Participants 
 
Twelve individuals with type 2 diabetes and no known cardiovascular disease (CVD) were 
recruited from Sheffield Teaching Hospitals diabetes outpatient clinics. Patients had been 
prescribed one or more oral hypoglycemic agents and/or glucagon-like-peptide -1 (GLP-1) 
analogue or insulin for less than two years. Eleven nondiabetic, age, BMI matched subjects 
were recruited from staff at the University of Sheffield and Sheffield Teaching Hospitals. 
Nondiabetic participants had fasting plasma glucose (<7mmol/L) and HbA1c <6.5% 
(<48mmol/mol) as measured using ion exchange high performance liquid chromatography. 
Participants taking beta-blocking agents or QT prolonging medications were excluded. 
Written informed consent was obtained from all participants and the study had received local 
ethics approval. 
Baseline assessment 
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Cardiovascular autonomic reflex tests were performed as previously described (10) following 
a recent consensus statement (11). All patients were euglycemic at the time of autonomic 
function testing. Individuals with two or more abnormal cardiovagal tests were regarded as 
having definite cardiac autonomic neuropathy and excluded. Spontaneous cardiovagal 
baroreceptor sensitivity (BRS) was obtained using a Portapres (Finapres Medical Systems, 
Amsterdam, The Netherlands). BRS analysis was performed using dedicated software based 
on the sequence method (Nevrokard v5.1.3, Intellectual Services, Slovenia) (12). All 
participants had a normal 12 lead electrocardiogram at baseline.    
Hyperinsulinemic clamp protocol 
All subjects participated in paired hyperinsulinemic euglycemic and hypoglycemic studies 
separated by at least 4 weeks. Participants were fasted from midnight and were instructed to 
avoid caffeine and vigorous exercise 24 hours prior. No symptomatic hypoglycemia or a 
capillary blood glucose <3.0mmol/L occurred in the previous 24 hours in all participants.  
Participants attended the Clinical Research Facility at 8am after an overnight fast. In the 
diabetic group, the blood glucose was initially stabilized between 6-7mmol/L using a variable 
low dose intravenous insulin infusion. An intravenous cannula was inserted into the 
antecubital fossa of the non-dominant arm for insulin and dextrose infusion. A retrograde 
cannula was inserted in the non-dominant hand in a warming chamber at 55
o
C for blood 
glucose and catecholamine sampling. During euglycemic and hypoglycemic clamps in both 
groups, a primed continuous intravenous insulin infusion was administered at 120mU/m
2
/min 
along with 20% dextrose at a variable rate, adjusted according to blood glucose 
concentrations every five minutes.  Arterialized whole blood glucose was measured in 
duplicate using a glucose oxidase method (Yellow Springs Instrument 2300STAT, Ohio, 
USA). In the hypoglycemic clamp glucose was lowered from euglycemia to 2.5mmol/L over 
60 minutes (T0 to T60), thereafter maintained at 2.5mmol/L for a further 60 minutes (T60-
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T120). In the euglycemic clamp, arterialized whole blood glucose was maintained at 
6mmol/L for the duration of the study (120 minutes). Participants were blinded to blood 
glucose values. 
Heart rate variability and blood pressure 
ECG signals were obtained using a 3 lead ECG monitor (Ivy Cardiac Trigger Monitor 3000, 
Ivy Biomedical Systems Inc., Branford CT, USA), digitized at a sampling frequency of 
200Hz) and recorded using WR-TestWorks™ software (version 2.4.0, WR Medical 
Electronics Co.). ECG recordings for HRV were performed at 30 minute intervals during the 
clamp study (Baseline, T30, T60, T90, T120). Heart rate variability was determined from 5 
minute resting recordings with the participant supine and free breathing. Manual editing of 
RR intervals was performed along with visual inspection of QRS complexes to exclude any 
ectopic beats and artifacts. Normal RR intervals (NN) were extracted in the time domain and 
frequency domain heart rate variability analysis was performed in accordance with 
recommendations of the Taskforce on Heart Rate Variability (13). Fast Fourier 
Transformation was applied to 5-minute segments of RR intervals for frequency domain 
analysis and the power of heart rate variability was calculated within the low frequency (LF) 
(0.04-0.15 Hz) and high frequency (HF) bands (0.15-0.4 Hz) (13). The power in the HF band 
reflects parasympathetic activity. The ratio between the LF power and total power (LF power 
+ HF power) was calculated (LFnorm), which indicates the level of sympathetic modulation 
in heart rate variability (14; 15).  
Blood pressure was measured every 30 minutes using an automated oscillometric 
sphygmomanometer (DINAMAP ®GE Medical Systems Information technologies, Inc.) 
after at least 5 minutes in a supine position. Pulse pressure was calculated as systolic blood 
pressure (SBP) minus diastolic blood pressure (DBP).  
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Cardiac repolarization 
To assess cardiac repolarization, high resolution 12 lead ECGs were recorded for five 
minutes at the onset (T60) and end of hypoglycaemia or euglycemia (T120) in a Mason-Likar 
(16) configuration with the subject lying supine. Signals were sampled at 1200 Hz and 
amplified using g®.USBamp amplifier (g.tec Medical Engineering, GmbH, Austria) and 
recorded with g.®Recorder software (g.tec Medical Engineering, GmbH, Austria). All pre-
processing and data analysis was performed using custom built software in Matlab (The 
Mathworks, Inc.). The ECG signals were bandpass filtered between 0.2 and 40 Hz. Beat 
averaging was then performed on 5 minute segments using template matching to improve the 
signal to noise ratio. The repolarization analysis was based on a composite wave, calculated 
from averaged beats from leads I, II and V5 (17).  
Measurement of the QT interval, from Q onset to T end, was based on the tangent method 
and Bazett correction for heart rate was applied. As the Bazett correction may overcorrect at 
higher heart rates, QT was also corrected according to the nomogram method (18) which has 
been validated for heart rates between 40 to 120 beats per minute. In addition to QT which 
represents duration of repolarisation, conventional measures of T wave morphology (T wave 
symmetry and T wave amplitude) were also calculated based on the composite waveform as a 
measure of heterogeneity of repolarization. T wave symmetry was defined as the area under 
the T wave from T onset to T peak divided by the T wave area between T peak to T end (19). 
The median T wave symmetry in normal individuals is 1.5 and T symmetry close to 1.0 is 
abnormal and associated with increasing risk of arrhythmias (20). The normalised T wave 
amplitude was calculated as the ratio of the T wave amplitude during clamp at each timepoint 
relative to the T wave amplitude at baseline.  
Additional measures of  T wave morphology were calculated using the principal 
component analysis (PCA),  derived from averaged beats from 8 ECG leads: lead I, lead II 
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and leads V1 to V6 as previously described (21). These provide more complex information 
on cardiac repolarisation that are unaffected by heart rate. PCA ratio was calculated as a ratio 
between the height and width of the T wave loop. An increased PCA ratio indicates a fatter T 
wave loop and a more complex T wave morphology which is predictive of all-cause and CV 
mortality in the general population (22; 23), after myocardial infarction (MI) (24; 25) and in 
patients with diabetes (26). The T-wave loop dispersion (TWLD) represents the length of the 
loop and describes the temporal variation of interlead relationships during cardiac 
repolarisation. The total cosine R-to-T (TCRT) was calculated as the global angle between 
the main QRS and T wave vectors and describes the difference between the depolarisation 
and repolarisation wavefronts. Decreased TWLD and TCRT have been shown to be 
predictive of cardiac death post MI (24) and associated with arrhythmias post MI (25).  
Recordings were made at baseline, T60 and T120 minutes. Analysis of recordings was 
blinded to the glucose concentration. 
Biochemical analysis 
For measurement of catecholamines, 6ml whole blood was collected into chilled lithium 
heparin tubes containing 50 microlitres of EGTA/glutathione preservative and centrifuged at 
4 
o
C, 3000 rpm for 10 minutes. The resulting supernatant was stored at -80 
o
C until assayed 
by high performance liquid chromatography. Plasma free insulin was analysed by an 
immunometric assay (Invitron Insulin ELISA, Invitron Ltd, Monmouth, UK) following 
precipitation with polyethyelene glycol. Serum potassium was analysed using an automated 
system (Roche Cobas, Roche Diagnostics, United Kingdom), using the direct ion selective 
electrode method. Biochemical parameters were measured at baseline and 120 minutes during 
all clamps. 
Statistical analysis 
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Data that followed an approximate normal distribution were summarised using mean±SE 
unless otherwise stated, whilst skewed data were summarised using the median (interquartile 
range). 
Within each participant group, autonomic and repolarization parameters were analyzed using 
two way repeated measures ANOVA where both time and glycemic arm were specified as 
repeated factors. The Greenhouse Geisser correction was applied where sphericity was 
violated. Planned contrasts were made versus baseline and also between euglycemia and 
hypoglycemia at equivalent time points with Sidak’s correction for multiple comparisons. To 
compare changes in repolarization in diabetic versus nondiabetic subjects, two way repeated 
ANOVA was performed with glycemic arm as a repeated factor. Planned contrasts were 
made for the effect of group and glycemic arm with Sidak’s correction for multiple 
comparisons. Catecholamines, glucose and potassium at T120 were compared under 
euglycemic and hypoglycaemic conditions using a two way ANOVA with planned contrasts 
for the effect of the group (diabetes versus nondiabetic) and glycemic condition with Sidak’s 
correction for multiple comparisons. A nonparametric Kruskal-Wallis test was used to 
compare free insulin levels at T120 under euglycaemia versus hypoglycaemia and between 
groups.  Missing data were dealt with using casewise deletion. Analysis was performed using 
SPSS (version 20.0, IBM, Chicago, Illinois) and GraphPad Prism (version 6.04, Graphpad 
Prism Inc).  A p value of <0.05 was deemed statistically significant. 
Results 
Participant characteristics 
Participant characteristics are shown in Table 1. Patients with Type 2 diabetes were similar in 
age and BMI compared to the nondiabetic group. Five patients were taking oral 
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hypoglycemic agents only, 5 were taking a combination of oral hypoglycemic agents and a 
GLP-1 analogue and two had been taking oral hypoglycemic agent and basal insulin for less 
than two years.  Two diabetic patients were on ACE inhibitors and remained on them 
throughout the study. Diabetes patients tended to have higher baseline heart rates, blood 
pressure and lower HRV and BRS. Parameters of T wave repolarisation, including T wave 
amplitude, TWLD, PCA ratio and TCRT tended to be lower in the diabetic group at baseline 
compared with nondiabetic subjects; however, other measures, including QTc and T wave 
symmetry, were similar. 
Hyperinsulinemic clamp 
Target arterialized blood glucose levels are shown in Fig 1. Blood glucose concentrations 
were 5.81±0.29mmol/L and 5.96±0.18 mmol/L at the end of euglycemic clamp in diabetic 
and nondiabetic groups respectively with no significant differences between groups (mean 
difference -0.15, 95% CI -0.85 to 0.55 mmol/L, p = 0.86). At the end of hypoglycemia these 
were 2.56±0.22mmol/L and 2.56±0.09mmol in diabetic and nondiabetic groups respectively 
(mean difference 0.0, 95% CI -0.70 to 0.70 mmol/L, p >0.99). Free insulin levels at 120 
minutes were Median (IQR) 576 (468-627) pmol/L during euglycemia and 689 (477-1076) 
pmol/L during hypoglycemia in the diabetic group and 865 (509-952) pmol/L in the 
euglycemic and 665 (468-967) pmol/L in the hypoglycemic arms of the nondiabetic group 
respectively which were comparable across all four conditions (p = 0.23). 
Cardiac autonomic function 
Heart rate  
Baseline heart rates were higher among diabetic subjects. There were no significant changes 
in heart rate during euglycemia in either group (Fig 2 top panel, Table 2). In nondiabetic 
participants, heart rate increased from T60 and up to the end of the hypoglycemic clamp. 
Diabetic individuals showed a delayed maximal increase in heart rate at T90, after thirty 
21/12/2016 T2DM_clampHRV 
 
12 
 
minutes at hypoglycemic levels. However, there was a subsequent fall in heart rate towards 
baseline at T120, after sustained hypoglycemia of 1 hour (Fig 2 top panel). 
Heart rate variability 
In nondiabetic individuals, the frequency domain measure of vagal activity, log HF, 
decreased from T60, coincident with the rise in heart rate, and remained decreased till the end 
of hypoglycemic clamp (Fig 2 middle panel). In diabetic subjects, during hypoglycemia, log 
HF decreased maximally at T90. However, at T120 log HF returned to baseline levels 
suggesting reactivation of vagal tone coincident with a decrease of heart rate towards 
baseline. This did not occur in nondiabetic participants (Fig 2 middle panel, Table 2). Similar 
trends were observed by time domain analyses. RMSSD, a time-domain measure of vagal 
activity decreased at T90 following hypoglycemia but returned to baseline levels at T120 in 
diabetic subjects (Supplementary material, Table 1). In nondiabetic participants, normalized 
low frequency power, a marker of relative sympathetic contribution, increased at T30 during 
hypoglycemia compared with a decrease in the euglycemic clamp. In diabetic participants 
LFnorm did not change significantly over time in either glycemic condition (Fig 2 bottom 
panel). 
Blood pressure 
Systolic, diastolic blood pressures and pulse pressure did not change significantly during 
euglycemia in either group (Fig 3 top panel, Table 2). SBP did not change during 
hypoglycemia in nondiabetic participants but tended rise in SBP in diabetic participants 
(Table 2). There was a smaller decline in DBP among T2DM as compared with nondiabetic 
individuals (maximum change Δ-6±10 mmHg versus Δ-11.3±5.93 mmHg respectively, Fig 3 
middle panel). DBP continued to decline till the end of the hypoglycemic clamp in 
nondiabetic participants, with the minimum DBP occurring at median (IQR) 120 (105-120) 
minutes compared to 90 (82.5-90) minutes in diabetic group. During hypoglycemia, there 
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was a significant increase in pulse pressure in diabetic participants (p=0.02 for interaction 
between time and glycemic arm) which was more abrupt than in nondiabetic individuals (Fig 
3 bottom panel).   
Cardiac repolarization 
Cardiac repolarization data are presented for 10 diabetic subjects and 9 nondiabetic subjects 
(Table 3 and Figure 4). In two diabetic and two nondiabetic subjects, repolarization analyses 
could not be performed at T120 due to technical issues relating to the ECG data which 
occurred at random. 
QTc 
There were significant, relatively small increases in corrected QT duration by Bazett’s 
formula (QTcB) in both diabetic and nondiabetic participants during euglycemic clamp at 
T120 (Table 3 and Figure 4). Compared with euglycemia, QTcB increased significantly more 
during hypoglycemia in both groups (Fig 4).  QTc B increased by Δ 57±5ms in nondiabetic 
participants and Δ 76 ±20 ms in diabetic participants during hypoglycemia. Although QTcB 
tended to increase to a larger extent in diabetic subjects, the difference did not reach 
statistical significance (mean difference 19, 95% CI -22 to 59 ms, p= 0.50). The maximum 
increase occurred at T120 in both groups. QT corrected by the normogram method (QTcN) 
exhibited similar trends, increasing by Δ 12±8 versus Δ 68±21 ms during euglycemia and 
hypoglycemia respectively among diabetic subjects (p = 0.003 for glycemic arm). QTcN 
increased by Δ18±11 versus Δ56±13 ms during euglycemia and hypoglycemia respectively in 
nondiabetic subjects (p=0.06 for glycemic arm), with no significant differences between 
groups in euglycemic or hypoglycemic responses.   
T wave morphology  
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T wave symmetry, an index of T wave morphology fell by a similar extent in nondiabetic 
subjects during euglycemia and hypoglycemia (Fig. 4 middle panel). However, in diabetic 
subjects T symmetry decreased significantly more during hypoglycemia compared with 
euglycemia, resulting in more abnormally shaped, symmetrical T waves. There was a 
significant difference in the change in T symmetry during hypoglycemia between diabetic 
and nondiabetic groups (mean difference Δ – 0.33, 95% CI -0.62 to -0.03, p= 0.03).  The 
amplitude of the T waves, normalised to the baseline (Tamp norm) fell during both 
euglycemia and hypoglycemia in both groups by a similar extent (Table 3). Repolarization 
and wavefront propagation parameters derived from principle component analysis are shown 
in Table 3.  The PCA ratio, which describes the complexity of the T wave morphology across 
the 12 ECG leads, did not change during euglycemia in either group. The PCA ratio 
significantly increased during hypoglycemia in diabetic participants (Δ 0.16±0.05), indicating 
higher complexity, compared with no change in nondiabetic participants (Δ 0.01±0.05) 
(p=0.03 for difference between groups). The T wave loop dispersion (TWLD), which 
indicates temporal variation in interlead relationships, decreased similarly across glycemic 
conditions in both groups. No significant changes occurred for the wavefront direction 
descriptor (TCRT) in either glycemic arm for both groups.   
Biochemical measurements 
Baseline levels of catecholamines were similar between diabetic and nondiabetic subjects 
(p=0.99). Catecholamines were significantly higher at the end of hypoglycemia versus 
euglycemia in both groups (all p<0.01) (Table 4). Epinephrine levels at end of hypoglycemia 
were 3.05±0.71 nmol/L and 3.83±0.85 nmol/L in diabetic and nondiabetic individuals 
respectively, a difference which was not statistically significant (p=0.54). Peak 
norepinephrine at the end of hypoglycemia were 2.45±0.23nmol/L and 2.69±0.44 nmol/L in 
diabetic and nondiabetic subjects respectively, a difference between the two groups which 
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was not statistically significant (mean difference -0.24, 95% CI -0.11 to 0.58 nmol/L, 
p=0.75). 
 In the nondiabetic group, potassium levels were not significantly different during 
hypoglycemia versus euglycemia (3.48±0.11 mmol/L versus 3.69±0.14 mmol/L respectively, 
p = 0.40). However, in the diabetic group, potassium was significantly lower at the end of 
hypoglycemic clamp compared with euglycemia (3.27±0.09mmol/L versus 
3.72±0.13mmol/L, p=0.02). Potassium levels at the end of hypoglycemic clamp tended to be 
lower in diabetic subjects but the difference did not reach statistical significance (mean 
difference -0.21, 95% CI -0.60 to 0.17 mmol/L, p = 0.39). 
Discussion 
The main findings of this study are as follows. 1) In individuals with type 2 diabetes, 
hypoglycemia resulted in transient increases in heart rate with coincident vagal withdrawal, 
followed by a relative decrease in heart rate during more sustained hypoglycemia of one hour 
accompanied by vagal reactivation (shown by increased HF power and RMSSD). In 
nondiabetic subjects this did not occur and there was continued vagal inhibition throughout 
hypoglycemia. 2) There were greater repolarization abnormalities as shown by QTc and T 
wave morphology measures in type 2 diabetes subjects despite similar levels of 
hypoglycemia. 
Diabetic participants exhibited impaired baseline autonomic function compared with 
nondiabetic subjects, with higher resting heart rates and lower HRV although none had frank 
autonomic neuropathy by formal testing of cardiovascular reflexes. In the nondiabetic group, 
subjects demonstrated continued vagal withdrawal as evidenced by decreased high frequency 
HRV throughout hypoglycemia.  This is consistent with previous studies of experimental 
hypoglycaemia in healthy and type 1 diabetic participants (27; 28). In contrast, following 
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initial increases in heart rate and vagal withdrawal, we observed a slowing of heart rate in 
diabetic subjects after 60 minutes of hypoglycemia (T120) with vagal reactivation. We 
observed a similar phasic response in heart rate during spontaneous prolonged hypoglycemia 
in type 2 diabetes patients in our previous ambulatory study with some patients 
demonstrating profound bradycardia accompanied by ectopic activity (6). Reasons for the 
differences between the diabetic and non-diabetic groups in this study are unclear. The 
arterial baroreflex is a negative feedback reflex that regulates arterial pressure around an 
operating point. Baroreceptor sensitivity describes the degree to which the heart rate 
increases or decreases in response to a given change in mean arterial pressure as a 
consequence of the baroreflex. In detailed experimental studies of nondiabetic and type 1 
diabetic participants, baroreceptor sensitivity has been shown to fall during experimental 
hypoglycemia along with resetting of the working range to higher heart rates (29; 30). It is 
possible that in diabetic subjects, a failure of baroreceptors to reset to higher heart rates could 
lead to an increase in vagal restraint in the face of sustained sympathetic stimulation, rising 
SBP and pulse pressure as the operating point remains at baseline levels. Impaired acute 
resetting of the baroreceptor operating point has also been reported among hypertensive 
individuals (31). Future studies could examine this hypothesis with concurrent measurements 
of baroreceptor function during experimental hypoglycaemia in type 2 diabetic patients. 
During hypoglycaemia, maximal changes in heart rate and decline in high frequency 
HRV occurred later in diabetic individuals at T90 as compared with nondiabetic individuals 
in which they occurred at T30. Delayed increments in heart rate and cardiac output responses 
during hypoglycaemia have previously been reported in intensively treated type 1 diabetic 
individuals, and may reflect blunted counterregulatory hormonal responses (32).  However, in 
this study epinephrine and norepinephrine levels during hypoglycaemia were similar between 
type 2 diabetic and nondiabetic groups.  
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We have also shown greater abnormalities in duration and heterogeneity of repolarization 
during hypoglycemia in diabetic participants. Changes in the morphology of the T wave, both 
symmetry (T wave symmetry) and complexity across the leads (PCA ratio) were  greater 
during hypoglycemia in diabetic subjects. This suggests greater dispersion of repolarisation, 
which is proarrhythmic and has been linked with increased cardiovascular risk (22; 23; 33).  
These T wave changes during hypoglycaemia have not been previously described in the type 
2 diabetic population and the differences compared to non-diabetic individuals are 
noteworthy.  
A stronger sympathoadrenal response is unlikely to be the primary explanation as the peak 
epinephrine levels were similar in both groups but might be the result of greater declines in 
serum potassium, which we observed during hypoglycemia in diabetic subjects. It is possible 
that autonomic dysfunction in individuals with diabetes might, through denervation metabolic 
adrenergic hypersensitivity lead to a greater beta-adrenoreceptor mediated fall in potassium.  
This would be analogous to those observed in other responses, such as free fatty acid 
production during experimental hypoglycaemia among subjects with type 1 diabetes and 
autonomic dysfunction  (34). This mechanism could be explored in future experimental 
studies involving potassium clamping or adrenergic blockade. 
Previous studies have shown a relationship between potassium and T wave amplitude 
during hyperinsulinemic hypoglycaemia (35; 36). Our group has previously shown that 
replacement of potassium during hyperinsulinemic clamps reversed increases in QT 
dispersion but not QTc duration during hypoglycemia in nondiabetic individuals (37). 
However, we cannot exclude the possibility that this could also be related to intrinsic 
abnormalities in repolarisation substrate among diabetic participants that are exacerbated by 
hypoglycemia.  Interestingly, differences have also been reported in animal models of 
experimental hypoglycemia where diabetic mice were at greater risk of arrhythmias than 
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nondiabetic counterparts (38). The underlying mechanisms require further testing in 
experimental studies. 
One strength of the present study is that cardiovascular variables were measured at 
multiple time points during hypoglycemia. Previous studies have shown increases (39), 
decreases (35) or no change (36) in vagal power during hyperinsulinemic hypoglycaemia in 
type 1 diabetic and nondiabetic individuals.  These discrepant data may reflect measurements 
at a single, often variable timepoint, an explanation supported by the present study, indicating 
that changes in cardiac autonomic tone appear phasic and depend on duration of 
hypoglycemia.  
Our study had some limitations. It proved challenging to control for the depth and 
frequency of breathing during HRV recordings which may affect the HF component of HRV, 
an index of vagal activity (14). In the original protocol, participants were asked to pace their 
breathing at 12 breaths/minute (0.2 Hz) by following a timed visual display, but failed to 
comply consistently during hypoglycemia, perhaps due to cognitive impairment. However, 
the mean spontaneous respiratory frequencies across five minutes of recording were 
consistently situated in the middle of the HF frequency band, around 0.25 Hz. Differences 
between experimental conditions were small and unlikely to significantly affect the HRV 
spectra and the estimation of vagal activity and its changes during the protocol 
(Supplementary material Table 2). 
 There are relevant differences between our experimental model of sustained 
hyperinsulinemic hypoglycaemia and spontaneous clinical episodes. In this study, although 
heart rate tended to fall towards baseline during sustained hypoglycemia with vagal 
reactivation, we did not observe profound bradycardia as we previously reported during 
spontaneous prolonged nocturnal episodes in an observational clinical study (6). These 
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differences could be related to circadian variation as experiments were conducted during the 
day. During the night, background vagal tone tends to be greater and sympatho-adrenal 
responses to hypoglycaemia are suppressed during sleep which may lead to greater vagal 
predominance (40). Spontaneous nocturnal episodes were generally more prolonged and 
reached lower glucose values than those induced during the current study (which might also 
explain the relatively modest changes in heart rate).  We limited the duration (60 minutes) 
and depth (2.5 mmol/L) of experimental hypoglycemia for ethical reasons and it is possible 
that duration and depth of hypoglycaemia may also play a role. Experimental hypoglycemia 
is associated with greater decline in potassium and catecholamine flux which could lead to 
exaggerated repolarisation abnormalities. However, the magnitude of QT prolongation 
observed here, has been reported in clinical settings. In a retrospective cohort study of type 2 
diabetes patients presenting to the emergency room with severe hypoglycemia, 14% had QTc 
in excess of 500ms on presentation and up to a third had hypokalemia (41). 
The present study suggests that abnormal repolarization and autonomic tone interact 
differentially depending upon duration of hypoglycemia. Thus autonomic dysfunction in the 
patients with diabetes may contribute to the different time-course in vagal tone between the 
two groups as well as the more pronounced abnormalities in some measures of cardiac 
repolarization. This interaction might also explain the different patterns of arrhythmias we 
previously observed during our ambulatory clinical study (6). Using a rodent model of 
experimental hypoglycemia, Reno and colleagues have observed arrhythmias ranging from 
QT prolongation, ventricular ectopy to heart block that was dependent on duration and 
severity of experimental hypoglycemia in mice (38).  In the present study, sustained 
experimental hypoglycemia was associated with later reactivation of vagal tone in diabetic 
subjects, despite sustained increased in circulating catecholamines. Of note this occurred 
when QT prolongation and T wave changes were at their maximal.   
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In conclusion, our data indicate that cardiac autonomic regulation during 
hypoglycemia appears to be time-dependent and different between those with type 2 diabetes 
and nondiabetic subjects. This may be explained by differential hemodynamic effects in 
response to hypoglycemia. In type 2 diabetes, the initial heart rate increment to hypoglycemia 
was delayed and there was reactivation of vagal activity during sustained hypoglycemia. 
Individuals with type 2 diabetes also exhibited greater repolarization abnormalities compared 
to those without diabetes, despite a similar hypoglycemic stimulus and comparable 
catecholamine levels. These mechanisms could contribute to arrhythmias that have been 
reported during clinical hypoglycemic episodes.  Our data provide further evidence 
supporting a possible relationship between hypoglycemia and increased cardiovascular 
mortality in type 2 diabetes and highlight the potential contribution of autonomic 
dysfunction.  
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Table 1 Participant characteristics 
Data are mean ± SE except age as median (interquartile range). HbA1c – glycated 
hemoglobin SBP - systolic blood pressure; DBP - diastolic blood pressure; HR - heart rate;  
BMI - body mass index; QTcB – corrected QT by Bazzett’s formula; QTcN – corrected QT 
by nomogram method; TWLD - T wave loop dispersion; TCRT – total cosine R to T; PCA 
ratio – principal component analysis ratio; SDNN – standard deviation of normal RR 
intervals; RMSSD - root mean square of the difference of successive R-R intervals; log HF - 
log high frequency power; LFnorm- normalized low frequency power; BRS – baroreceptor 
sensitivity  
 
 
  
 nonDM 
n=11 
T2DM 
n=12 
Age (years) 52 (34-63) 53.5 (37-64) 
Male   (M/F) 5/6 9/3 
BMI (kg/m
2
) 31 ± 2 34 ± 1 
Duration of diabetes (years) n/a 11 ± 2 
HbA1c (%) 5.5 ±0.3 7.8 ± 0.4 
            (mmol/mol IFCC) 34±3 62 ± 4 
SBP (mmHg) 131 ± 5 135 ± 4 
DBP (mmHg) 72 ± 3 82 ± 3 
HR (bpm) 64 ±2 78 ± 2 
Repolarization   
QT (ms) 406±9 381±8 
QTcB (ms) 412±8 417±6 
QTcN (ms) 410±7 406±4 
T wave amplitude (µV) 466±84 399±35 
T wave symmetry 1.44±0.06 1.55±0.06 
TWLD 1415±257 1279±75 
TCRT 0.78±0.06 0.69±0.08 
PCA ratio 0.10±0.03 0.08±0.02 
Heart rate variability   
SDNN (ms) 48.2±4.4 27.4±3.4 
RMSSD (ms) 32.9±4.6 15.5±7.94 
Log Total power  (ms
2
) 2.90±0.11 2.34 ± 0.10 
Log HF (ms
2
) 2.32±0.14 1.85± 0.11 
LFnorm 0.70±0.04 0.65±0.04 
BRS (ms/mmHg) 11.51±2.31 8.59±1.18 
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Table 2 Heart rate variability and blood pressure during euglycemia and hypoglycemia 
in type 2 diabetes and nondiabetic subjects 
euglycemia (EU)  hypoglycemia (HYPO) HR - heart rate; bpm - beats per minute; log HF -  
high frequency power; SBP systolic blood pressure; DBP diastolic blood pressure. Data 
Mean ±SE  
 nonDM DM 
Timepoint EU HYPO EU HYPO 
HR (bpm)     
0 62±3 62±3 73±3 72±3 
30 63±3 62±3 75±3 73±3 
60 61±3 67±4 76±3 75±3 
90 64±3 64±4 74±3 77±3 
120 63±3 64±3 73±3 71±2 
     
Log HF     
0 2.18±0.16 2.36±0.13 1.87±0.14 1.89±0.18 
30 2.33±0.14 2.29±0.13 1.71±0.17 1.86±0.17 
60 2.30±0.13 2.14±0.15 1.75±0.15 1.65±0.19 
90 2.20±0.13 2.15±0.15 1.78±0.15 1.56±0.18 
120 2.22±0.12 2.15±0.15 1.82±0.14 1.79±0.23 
     
SBP (mmHg)     
0 128±6 121±4 136±5 136±5 
30 129±8 125±6 134±4 135±5 
60 126±5 126±6 138±6 141±5 
90 128±5 128±7 139±5 144±7 
120 126±5 124±7 138±6 134±4 
     
DBP (mmHg)     
0 75±4 74±3 77±2 77±2 
30 75±4 69±4 75±3 77±2 
60 75±3 68±3 77±3 73±3 
90 73±3 67±3 76±2 71±4 
120 73±3 62±3 78±4 72±3 
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Table 3: Change in cardiac repolarization  among diabetic and nondiabetic individuals 
during euglycemia and hypoglycemia 
Change in measures of repolarisation at time 120 as compared with baseline. Two way 
repeated measures ANOVA with multiple comparisons between glycemic arms (euglycemia 
versus hypoglycaemia) and between subjects groups; * indicates significant difference 
between diabetic and nondiabetic participants within each glycemic arm. Data from 9 
nondiabetic (nonDM) and 10 diabetic (DM) subjects. Data (Mean ±SE).   nonDM – 
nondiabetic; DM – diabetic; QTc- corrected QT duration;  Tamp norm- normalised T wave 
amplitude; TWLD - T wave loop dispersion; PCA ratio – principle component analysis ratio; 
TCRT - total cosine R to T 
 
Table 4: 
Biochem
ical 
paramet
ers at 
end of 
clamp in 
diabetic 
and 
nondiab
etic 
individu
als 
Data 
(Mean 
±SE). p 
value 
comparis
on 
between 
EU 
(euglyce
mia) and 
HYPO 
(hypogly
cemia) 
by two 
way 
ANOVA 
with 
multiple 
comparis
ons 
between 
glycemic 
arms and 
 Change from baseline EU vs HYPO 
Adjusted p value 
 EU HYPO  
QTc (ms)    
nonDM Δ21±4 Δ57±5 0.08 
DM Δ14±4 Δ76±20 0.0009 
    
T symmetry     
nonDM Δ-0.22±0.04 Δ -0.20±0.06 0.98 
DM Δ-0.21±0.06 Δ -0.52±0.14* 0.09 
    
Tamp norm    
nonDM Δ-0.41±0.06 Δ-0.32±0.18 0.74 
DM Δ-0.43±0.04 Δ-0.57±0.06 0.42 
    
TWLD    
nonDM Δ-476±64 Δ-404±243 0.90 
DM Δ-452±41  Δ-576±53 0.70 
    
PCA ratio    
nonDM Δ 0.03±0.02 Δ 0.01±0.05 0.90 
DM Δ 0.04 ± 0.02 Δ 0.16 ±0.05* 0.03 
    
TCRT    
nonDM Δ-0.01±0.04 Δ-0.002± 0.08 0.93 
DM Δ-0.05±0.17 Δ  0.02±0.15 0.99 
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between subject groups.  There were no significant differences between nondiabetic (nonDM) 
and diabetic (DM) groups under either glycemic condition. 
 
 EU HYPO EU vs HYPO  
Adjusted p 
value 
Potassium (mmol/L)    
nonDM 3.69±0.14 3.48±0.11 0.40 
DM 3.72±0.13 3.27±0.09 0.02 
    
Epinephrine (nmol/L)    
nonDM 0.14±0.02 3.83±0.85 0.0002 
DM 0.16±0.05 3.05±0.71 0.003 
    
Norepinephrine 
(nmol/L) 
   
nonDM 1.56±0.12 2.69±0.44 0.002 
DM 1.27±0.09 2.45±0.23 0.009 
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Figure 1: Arterialised blood glucose during hyperinsulinemic euglycemic and 
hypoglycemic clamps 
Open circle - Euglycemic clamp nondiabetic group; open square euglycaemic clamp diabetic 
group; closed circle – hypoglycaemic clamp nondiabetic group; closed square hypoglycaemic 
clamp diabetic group; Data mean (SE) 
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Figure 2: Heart rate and change in heart rate variability during hypoglycemia in type 2 
diabetes and nondiabetic participants 
* p<0.05 **<0.01  compared with baseline † p<0.05 euglycemia (EU) vs hypoglycemia 
(HYPO); HR - heart rate; bpm - beats per minute; log HF -  high frequency power, index of 
parasympathetic activity; LFnorm - normalized low frequency power, index of sympathetic 
modulation; Data Mean (SE). Open circle - Euglycemic clamp nondiabetic group; open 
square euglycaemic clamp diabetic group; closed circle – hypoglycaemic clamp nondiabetic 
group; closed square - hypoglycaemic clamp diabetic group  
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Figure 3: Blood pressure during hypoglycemia and euglycemia in type 2 diabetes and 
nondiabetic participants 
Data Mean (SE). * p<0.05, p**<0.01, *** p <0.001, ****p<0.0001 compared with baseline. 
† p<0.05, †† p<0.01, †††† p<0.0001 euglycemia (EU) vs hypogycemia (HYPO) at equivalent 
timepoint.  SBP - systolic blood pressure; DBP - diastolic blood pressure; MAP - mean 
arterial pressure. Data are mean (SE). Open circle - Euglycemic clamp nondiabetic group; 
open square euglycaemic clamp diabetic group; closed circle – hypoglycaemic clamp 
nondiabetic group; closed square - hypoglycaemic clamp diabetic group 
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Figure 4: Changes in cardiac repolarisation during hypoglycaemic and euglyacemic 
clamps in diabetic and nondiabetic subjects 
Data Mean (SE). * p<0.05, p**<0.01 compared with baseline. † p<0.05, †† p<0.01 
euglycemia (EU) vs hypogycemia (HYPO) at equivalent timepoint. Data from 9 nondiabetic 
and 10 diabetic participants. QTcB – corrected QT duration using Bazett’s correction; TS – T 
wave symmetry, index of T wave morphology; PCA ratio – Principal component analysis 
ratio, index of complexity of the T wave morphology between the 12 leads. 
